RocketTickers

FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients

Long
NASDAQ:AMGN   Amgen Inc.
AMGN: Amgen
2018-12-14 16:00:00
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.